Clinical Trial Detail

NCT ID NCT02320292
Title Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Mayo Clinic
Indications

follicular lymphoma

Therapies

Rituximab

Ibritumomab tiuxetan + Rituximab

Age Groups: adult senior

No variant requirements are available.